Amol Akhade: Avutometinib + Defactinib in Recurrent LGSOC
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X about a recent study by Susana N. Banerjee et al. published in JCO:
“New JCO Study: ENGOT-OV60/RAMP 201
Avutometinib (MEK1/2 inh) + Defactinib (FAK inh) in recurrent LGSOC
Dual MAPK + FAK blockade = tumor + stroma suppression
Efficacy:
- ORR 31% overall
- 44% in KRAS-mut vs 17% WT
- PFS: 22.0 mo (KRAS-mut), 12.8 mo (WT)
- DOR: 31.1 mo
KRAS-mutant tumors = MAPK addicted = better MEK+FAK response
Responses even post-MEKi!”
Title: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Journal: JCO
Authors: Susana N. Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D’Hondt, Bradley J. Monk, Andrew Clamp, Emily Prendergast, Ana Oaknin, Kari Ring, Nicoletta Colombo, Robert W. Holloway, Manuel Rodrigues, Hye Sook Chon, Charlie Gourley, Alessandro D. Santin, Premal H. Thaker, Christine Gennigens, Gregg Newman, Erin Salinas, Hagop Youssoufian, Kathleen N. Moore, Stephanie Lustgarten, David M. O’Malley, Toon Van Gorp, Rachel N. Grisham
More posts featuring Amol Akhade on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023